LQDA Chief Commercial Officer Moomaw Scott Sells $252K of Stock

Scott Moomaw, the Chief Commercial Officer of Liquidia Corporation, sold 8,863 shares of the company on October 12, 2026. The shares were sold at $28.48 each, bringing in about $252,418.24. This sale was made under a planned trading arrangement.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. has 10,788,586 shares of Liquidia Corporation, valued at about $370.6 million after increasing its holdings by 5,299,329 shares. Farallon Capital Management LLC holds 8,365,038 shares, but reduced its stake by 290,837 shares, worth approximately $287.3 million. Caligan Partners, LP remains steady with 8,118,892 shares, while Findell Capital Management LLC has 3,502,112 shares. Vanguard Capital Management LLC added 212,206 shares, bringing its total to 3,139,183 shares valued at about $107.8 million.

Liquidia Corporation Stock Down 2.9%

The stock of Liquidia Corporation recently traded around $33.77 as of October 16, 2026. This price is significantly below its 50-day moving average of $61.62 and its 200-day average of $53.93. The stock also sits 63.9% below its 52-week high of $93.61, although it is 53.9% above its 52-week low of $21.94.

Recent Earnings

Liquidia Corporation reported trailing twelve-month revenue of approximately $450.9 million. The company achieved an impressive revenue growth of 1,842.7% year-over-year. Its earnings per share (EPS) for the same period stood at $1.39, reflecting a strong performance. The next earnings report is set for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Moomaw's sale, several other insiders also sold shares. Dana Boyle, an officer, sold 5,892 shares at $28.48, totaling about $167,804. Sanjeev Khindri, another officer, sold 1,101 shares for about $31,356. Michael Kaseta, the Chief Operating Officer, sold 18,938 shares valued at approximately $539,354. Jason Adair, also an officer, sold 7,301 shares for around $207,932.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia Corporation to an "Outperform" rating with a price target of $53.0, down from $106.0. BTIG also downgraded the stock to "Neutral." Needham maintained a "Buy" rating with a target of $72.0, reduced from $110.0. Wells Fargo downgraded the stock to "Equal-Weight" with a target of $30.0, down from $108.0. HC Wainwright & Co. maintained a "Buy" rating with a target of $58.0, down from $130.0. The consensus recommendation is a "Buy" with a mean price target of $54.38 based on eight analyst opinions.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing and commercializing treatments for rare cardiopulmonary diseases. Its lead product, YUTREPIA, is used for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Bottom Line

Investors will be watching Liquidia Corporation closely as it prepares to report earnings on November 3, 2026. Moomaw's sale, alongside other insider transactions, may signal shifting dynamics within the company. Analysts are adjusting their views on the stock, reflecting changing expectations in the market.